Elsevier

Journal of Diabetes and its Complications

Volume 30, Issue 8, November–December 2016, Pages 1519-1524
Journal of Diabetes and its Complications

Effects of Mediterranean diet on sexual function in people with newly diagnosed type 2 diabetes: The MÈDITA trial

https://doi.org/10.1016/j.jdiacomp.2016.08.007Get rights and content

Abstract

Aims

To assess the long-term effect of Mediterranean diet, as compared with low-fat diet, on sexual function in patients with newly diagnosed type 2 diabetes.

Methods

In a randomized clinical trial, with a total follow-up of 8.1 years, 215 men and women with newly diagnosed type 2 diabetes were assigned to Mediterranean diet (n = 108) or a low-fat diet (n = 107). The primary outcome measures were changes of erectile function (IIEF) in diabetic men and of female sexual function (FSFI) in diabetic women.

Results

There was no difference in baseline sexual function in men (n = 54 vs 52) or women (n = 54 vs 55) randomized to Mediterranean diet or low-fat diet, respectively (P = 0.287, P = 0.815). Over the entire follow-up, the changes of the primary outcomes were significantly lower in the Mediterranean diet group compared with the low-fat group: IIEF and FSFI showed a significantly lesser decrease (1.22 and 1.18, respectively, P = 0.024 and 0.019) with the Mediterranean diet. Baseline C-reactive protein levels predicted erectile dysfunction in men but not female sexual dysfunction in women.

Conclusions

Among persons with newly diagnosed type 2 diabetes, a Mediterranean diet reduced the deterioration of sexual function over time in both sexes.

Introduction

Type 2 diabetes is a prevalent chronic disease and shows no signs of abatement. According to the International Diabetes Federation, 415 million adults are estimated to currently have diabetes worldwide, with the alarming prediction of 642 million cases by the year 2040 (International Diabetes Federation, 2015). Vascular diabetic complications cause substantial human and economic burdens (Dall et al., 2014).

Type 2 diabetes has been associated with sexual dysfunction both in men (Penson et al., 2003) and in women (Pontiroli, Cortelazzi, & Morabito, 2013). A threefold increased risk of erectile dysfunction (ED) has been documented in diabetic men compared with nondiabetic men (Feldman, Goldstein, Hatzichristou, Krane, & McKinlay, 1994). Moreover, ED is a marker of significantly increased risk of cardiovascular disease (Dong, Zhang, & Qin, 2011) and all-cause mortality (Araujo et al., 2009); in a prospective study of 291 type 2 diabetic men with silent coronary artery disease (Gazzaruso et al., 2008), ED was associated with a twofold increase of cardiovascular morbidity and mortality after a mean follow-up of 47 months.

The association between diabetes and sexual dysfunction in women is less conclusive, although most studies have reported a higher prevalence of female sexual dysfunction (FSD) in diabetic women as compared with nondiabetic women (Miner, Esposito, Guay, Montorsi, & Goldstein, 2012). Some studies have reported an association between female sexual health and vascular risk factors, including type 2 diabetes, although no data support a clear role for FSD as a predictor of future cardiovascular events in diabetic women (Miner et al., 2012).

There is some evidence from clinical trials that sexual dysfunction is amenable to amelioration with interventions based on diet and lifestyle modification, both in men (Esposito et al., 2010, Esposito et al., 2004, Gupta et al., 2011) and in women (Esposito et al., 2007a, Wing et al., 2013). In the present study, we assessed male and female sexual function prospectively in participants in the MЀDITA trial. MЀDITA (MEditerranean DIet and Type 2 diAbetes) is a long-term randomized trial that demonstrated the superiority of Mediterranean diet, as compared with low-fat diet, in delaying need for diabetes medication in newly diagnosed type 2 diabetic subjects (Esposito et al., 2014, Esposito et al., 2009b).

Section snippets

Subjects

The MЀDITA trial was a single center, randomized, controlled trial aimed at prevention of diabetes drugs in type 2 diabetes by dietary intervention. The eligibility criteria for MЀDITA have been described elsewhere (Esposito et al., 2009b, Esposito et al., 2014). Briefly, participants were eligible for the trial if they had newly diagnosed type 2 diabetes never treated with antidiabetic drugs, age 30–75 years, body mass index (BMI) greater than 25 kg/m2, and hemoglobin A1c (HbA1c) level less than

Interventions

Originally, 215 men and women with newly diagnosed type 2 diabetes were randomized by using a computer-generated random-number sequence (simple randomization) at the baseline visit to one of two treatment diets, a Mediterranean diet (n = 108) or a low-fat diet (n = 107). The main goals of the dietary interventions were restriction of energy intake to 1500 kcal/day for women and 1800 kcal/day for men in both groups. The Mediterranean diet had the goal of no more than 50% of calories from carbohydrates

Baseline characteristics of participants

The present study comprised all the 215 participants who were eligible for the MЀDITA trial. The treatment groups were well matched for demographic and clinical characteristics (Table 1). The composition of the diets consumed by participants in the Mediterranean diet and low-fat diet groups was not different at baseline.

The baseline mean erectile function score was 21.9 in both groups of men assigned to the two treatment diets, with a similar distribution across the different categories of ED (

Discussion

The current study is the first long-term dietary trial to prospectively examine the effect of Mediterranean diet on sexual function in men and women with newly diagnosed type 2 diabetes. As compared with control low-fat diet, Mediterranean diet significantly delayed the deterioration of sexual function among high-risk persons who were initially free of sexual dysfunction. These results are to be viewed as conservative, because all participants in the low-fat group remained into the trial until

Acknowledgments

Funding/support: This study was supported in part by the Second University of Naples and the Associazione Salute con Stile.

Role of the funder/sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References (35)

  • RR Wing et al.

    Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial

    The Journal of Sexual Medicine

    (2010)
  • AB Araujo et al.

    Erectile dysfunction and mortality

    The Journal of Sexual Medicine

    (2009)
  • AT Beck et al.

    An inventory for measuring depression

    Archives of General Psychiatry

    (1961)
  • TM Dall et al.

    The economic burden of elevated blood glucose levels in 2012: Diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes

    Diabetes Care

    (2014)
  • KB De Salvo et al.

    Dietary Guidelines for Americans

    JAMA

    (2016)
  • K Esposito et al.

    Low-carbohydrate diet and coronary heart disease in women [letter]

    The New England Journal of Medicine

    (2007)
  • K Esposito et al.

    Mediterranean diet improves sexual function in women with the metabolic syndrome

    International Journal of Impotence Research

    (2007)
  • Cited by (61)

    • Poor quality of dietary assessment in randomized controlled trials of nutritional interventions for type 2 diabetes may affect outcome conclusions: A systematic review and meta-analysis

      2022, Nutrition
      Citation Excerpt :

      When collecting data, 21 studies [21–25],[27–42,44,45,47,48] incorporated multiple days of record/recall, and 16 studies [27–32,34,36–40,42,44,45,47] considered weekend variation. Nine studies [21–26,28,30,32,36,37,44,45] provided aids in portion size estimation, and seven of them used scales to measure food. Before data analysis, seven studies [30,31,34,39,43,47,48] provided a dietitian review of record/recall for clarification.

    View all citing articles on Scopus

    Trial registration clinicaltrials.gov Identifier: NCT00725257.

    Conflict of interest disclosures: Dr Esposito and Dr Giugliano reported receiving speaker fees from and serving on advisory boards for Merck Sharp & Dohme, Lilly, NOVO, and Sanofi. No other disclosures were reported.

    View full text